PBSC harvesting requires good quality venous access. The efficacy and complication rate of the venous access devices used during stem cell harvest in 101 consecutive patients were examined. Four different categories of venous access were used: (1) long-term dialysis central venous catheter (dCVC), (2) short-term dCVC, (3) peripheral venous cannulae (PVC), and (4) PVC and conventional central venous catheter. The number of harvest occasions per patient or harvest days per occasion were similar between the various categories of access. Complications during harvest occurred in 13 out of 48 (27%) occasions using a long-term dCVC compared to six out of 97 (6%) in the other three categories pooled together (P Ͻ 0.01). Forty-two of the 101 patients received a long-term dCVC to facilitate the harvest. The long-term dCVC was planned to stay in place and also be used as a conventional i.v. line during the following high-dose treatment. Twenty-one (50%) of the longterm dCVCs were removed due to complication. Thirteen (31%) of the long-term dCVCs were usable throughout the entire treatment period. In conclusion, we recommend that PBSC harvesting is performed through peripheral venous catheters when practically possible, otherwise via short-term dCVC. Keywords: PBSC collection; harvest; central venous access; central venous catheter; complication; thrombosis An increasing number of patients with various malignant disorders are undergoing high-dose therapy followed by autologous stem cells rescue as a part of their treatment. 1 PBSC collected by leukapheresis has become the main cell source in recent years. The procedure requires a high blood flow through intravenous (i.v.) lines between patient and apheresis machine. In some patients it is possible to use intravascular devices inserted in the peripheral arm veins, or to insert a femoral dialysis catheter. In other patients with a functional central venous catheter (CVC) already in place, this catheter can be used as the return line for blood from the leukaphereses machine to the patient. However, many patients need a double lumen central venous dialysis catheter (dCVC) to ensure harvesting. There are two different categories of dCVC, the stiff dCVC for short-term use 2 and the softer silastic dCVC for long-term use.
from the leukaphereses machine to the patient. However, many patients need a double lumen central venous dialysis catheter (dCVC) to ensure harvesting. There are two different categories of dCVC, the stiff dCVC for short-term use 2 and the softer silastic dCVC for long-term use. 3 The long-term type of dCVC can also be used for routine venous access, starting with delivery of chemotherapy for the mobilisation of stem cells through the period of highdose chemotherapy until bone marrow recovery. Most experience of long-term dCVCs has been collected in the haemodialysis setting. The majority of reported complications leading to removal of the long-term dCVCs are catheter-related infections (9-28%) [4] [5] [6] [7] and failure due to poor flow rates or thromboses (5-30%). 4, [6] [7] [8] [9] [10] The published experience on use of long-term dCVC for stem cell harvesting is limited. 3, 11, 12 In March 1993 we decided to use long-term dCVC for stem cell harvesting and high-dose therapy in patients unable to have peripheral venous cannulae (PVC) due to poor quality of the peripheral veins, with the intention of reducing the number of CVCs inserted in these patients.
The primary aim of this retrospective study was to estimate the function and complication rate of long-term dCVCs used during harvesting and as a conventional intravenous line. Secondly, we evaluated efficacy and complication rate during harvesting in all patients during the study period, comparing four different categories of venous accesses.
In summary, half of the long-term dCVCs were removed due to complications and only one-third of the long-term dCVCs were usable throughout the entire treatment period.
Patients and methods

Leukaphereses performed between 1993 and 1996
Between 1993 and 1996 101 patients were harvested on 145 occasions (each occasion consists of a varying number of harvests over a number of consecutive days (range 1-5 days)), over 363 leukapheresis days. Patient characteristics are summarised in Table 1 . In eight patients with CML, harvests were performed at the time of diagnosis and leukapheresed cells were saved as a back up to be used later during blast crisis. The remaining 93 patients were planned for PBSC rescue at the time of harvest.
Venous access routes used during harvest were divided into four categories: (1) long-term dCVC, (2) short-term dCVC, (3) PVC and (4) PVC and conventional CVC. In 66 of the 145 (46%) harvest occasions, patients had poor quality peripheral veins and dCVCs were inserted to facilitate the harvest procedure. In 18 of these 66 harvest occasions (16 patients), patients received a short-term dCVC (Mahurkar; Quinton Instruments). In the remaining 48 of these 66 harvest occasions (37 patients) PBSC were collected through long-term, tunneled, dual-lumen dCVC (PermCath; Quinton Instruments). Venous access could, in the same patient, differ from one harvest occasion to another, depending on the quality of the peripheral veins at the time of harvest.
Patients with a long-term dCVC
During the study period 42 patients received a long-term dCVC (Table 1) . Thirty-seven of these 42 patients mobilised stem cells and were subsequently harvested. The longterm dCVCs were surgically installed under aseptic conditions in an operating theatre. Patients with a platelet count Ͻ50 × 10 9 /l received prophylactic platelet transfusions before catheter insertion. Catheter placements are shown in Table 2 . Thirty-one of the 42 (74%) patients had a history of having had one to four previous CVCs. 
Leukapheresis procedure
Collection of peripheral stem cells was performed by apheresis nurses, using a COBE Spectra blood cell separator (Cobe, Lakewood, CO, USA) on standard settings of the automated program (presently software version 5.1) which has been upgraded regularly since the beginning of the study. Unless otherwise stated, at least 10 l of blood were processed during each procedure, aiming at a steady flow rate of 50-60 ml/min and a collection rate of р1.5 ml/min. All complications requiring special action during the aphereses were documented by the apheresis nurses.
Use and care of long-term dCVCs
dCVC dressings were changed twice a week in accordance with the findings of a previous study. 13 The exit site was aseptically cleaned with chlorhexidine (5%) and a transparent dressing was used. All parenteral therapy including medications, fluid therapy, blood products, peripheral stem cells and total nutrient admixtures were given via the longterm dCVC. Daily blood samples were also taken. Two three-way stopcocks with a 10-cm extension tube were connected to the long-term dCVC. The inner stopcock was changed at the time of the dressing change and the outside stopcock was changed once a day, most often directly after blood sampling. New caps were put on after every event.
The insertion site was inspected daily through the transparent dressing to identify early signs of infection. To maintain function between use, each lumen was primed with 1.3 ml or 1.4 ml of heparin (5000 IU/ml). Before each use the indwelling heparin was aspirated.
Impaired blood flow/occlusion
In long-term dCVCs with signs of occlusion (ie total failure of infusing or when it was possible to infuse but not to aspirate) saline flushes were administered. Fibrinolytic therapy (t-PA, Actilys; Boehringer Ingelheim) was used if catheter dysfunction persisted after mechanical manipulation. Suspicion of catheter-related deep venous thrombosis was confirmed either by X-ray or Doppler examination. Verification of a venous dCVC-related thrombosis resulted in immediate catheter removal. None of the patients received prophylactic oral anticoagulants.
Infection
The decision to remove a long-term dCVC due to infection, was made by the physician in charge. During neutropenia all patients received prophylactic antifungal and antiviral therapy with fluconazole 50-200 mg once daily and acyclovir 200 mg five times daily, respectively. Prophylactic antibiotic therapy was not given.
Statistics
Catheter survival analysis was calculated using the KaplanMeier life table method for estimating survival. Catheter survival times were recorded in completed days. Nominal data were compared using the Fisher's exact test. Differ-ences in group proportions were assessed by the MannWhitney U test. All statistical calculations were made with StatView 4.51 software.
Results
Efficacy and complication rate in all venous access devices used during leukaphereses performed 1993-1996
One hundred and forty-five harvest occasions were recorded in 101 patients. The number of harvest occasions per patient or harvest days per occasion were similar between the various types of access (Table 3) . Complications during harvest occurred on 13 out of 48 (27%) occasions when using a long-term dCVC compared to six out of 97 (6%) using other venous access devices pooled together (P Ͻ 0.01; Table 2 ).
When all harvest occasions were compared, without regard to the catheter category used, there was a statistically significant (P Ͻ 0.0001) difference in number of days per harvest occasion with more days during the first 2 years of this study compared to the last 2 years (data not shown).
There were more complications during harvest occasions in patients with lymphomas and solid tumours compared to the remaining patients (13 out of 43 (37%) vs six out of 102 (6%); P Ͻ 0.001).
Long-term dCVCs
Twenty-five of 42 patients completed the planned highdose treatment with autologous PBSC rescue. In 17 of these 25 patients the long-term dCVC was still in place at the time of PBSC rescue. Thirteen of the 17 long-term dCVCs were used without complications throughout the treatment period.
Three of 42 patients underwent allogeneic stem cell transplantation; in two of these three patients the initial long-term dCVC were removed electively and in one due to complications. Fourteen of 42 patients did not complete the planned high-dose treatment and PBSC rescue due to poor mobilisation, poor growth of CD34-positive cells (n = 6) or progressive disease or relapse (n = 8). In six of these 14 patients the long-term dCVC was still functioning well with no signs of infection or occlusion at removal.
The long-term dCVCs were inserted by 13 different sur- geons. There were no major operative complications. Minor bleeding from the insertion site was observed in 10 patients. There was a trend towards less complications leading to removal of catheters inserted in the external jugular vein (3/12, 30%) compared to the remainder (18/30, 60%; NS). A history of earlier lines did not increase the risk of a current catheter complication. Antibiotic prophylactic before insertion, blood values at the time of insertion, insertion time or bleeding after insertion, did not differ between patients in whom the long-term dCVC was later removed due to complications and those where it was not (data not shown). Pain, in the catheter site, requiring analgesics during the first 24 h after insertion was recorded in 30% of patients.
Twenty-one of 42 (50%) long-term dCVCs were removed electively after a median of 119 days (range 27-308). The remaining 21 catheters were removed after 47 days (median, range 21-176) due to complications; infection (n = 16), infection and thrombosis (n = 2), thrombosis (n = 2) and occlusion (n = 1; Figure 1 , P Ͻ 0.01).
In 11 out of the 18 long-term dCVCs removed due to clinically suspected infection, positive bacterial culture findings were obtained at the time of removal. In five patients the same microorganism was isolated from both blood and the long-term dCVC exit site (Coagulase-negative staphylococcus (CNS, n = 3), Staphylococcus aureus (n = 1) and Citrobacter freundii (n = 1)). Three patients had positive cultures in their blood (CNS (n = 1), S. aureus (n = 1) and Escherichia coli (n = 1)) and three patients had positive exit site cultures (CNS (n = 1), S. aureus (n = 1) and Corynebacter sp. (n = 1)). The remaining seven longterm dCVCs removed due to presumed infection had negative cultures.
Patients with malignant lymphoma showed a trend towards a higher complication rate compared to the other patients (9/12 (75%) vs 12/30 (40%); NS). There was no difference between patients with or without long-term dCVC complications with regard to the proportion of fever days (Ͼ38.0°C) during neutropenia (Ͻ0.5 × 10 9 /l; mean ± s.d., 54% ± 32 vs 38% ± 32 respectively; NS). However, patients with long-term dCVC complications had, when not neutropenic, a mean of 11 ± 18 febrile days per 100 catheter days. This can be compared to patients without complications, when not neutropenic, in whom a mean of 1% ± 2 febrile days (P Ͻ 0.001) was seen.
Earlier venous thrombosis was present in three of four patients with catheter-related thromboses compared to one of the remainder (3/4 (75%) vs 1/38 (3%); P Ͻ 0.001). During conventional use 20 of the 42 long-term dCVCs were occluded on 33 occasions, in one or both long-term dCVC lumen. Fibrinolytic therapy (Actilyse) was successful on 24 of 33 occasions. Seven occlusions were resolved by mechanic manipulation and one long-term dCVC required removal due to the occlusion.
Discussion
Central venous access is mandatory in the care of patients receiving intensive chemotherapy and harvest of peripheral stem cells is not possible without adequate access. There are several issues to consider when choosing a venous access device for patients planned for high-dose therapy with stem cell rescue.
When the peripheral route of venous access is deemed inadequate, one may choose a short-term dCVC, a shortterm femoral dialysis catheter or a long-term dCVC. The femoral catheter has to be removed immediately after the harvest and the risk of local bleeding must be considered. The short-term dCVC may allow repeated harvests during a consecutive number of days, but should not be in place for more than 10-14 days, thus necessitating at least one further catheter for the rest of the treatment period. To avoid unnecessary repeated trauma, a long-term dCVC can be used for the whole period.
We found no differences in harvest yield, expressed as days per harvest occasion, between the different access devices used in this study. Our presumption was that the more steady and often higher blood flow obtained by using a dCVC, compared to a PVC, would result in fewer harvest days per occasion. We are not aware of any trial comparing efficacy between different vascular access devices used for harvest.
In the first part of this study (1993) (1994) each patient was harvested more often, regardless of the type of i.v. device. There could be several explanations for this: (1) selection of more heavily pretreated patients, (2) PBSC mobilization with G-CSF was not used as a standard and (3) the target level of collected CD34
+ cells was higher during the early period. There were clearly more complications during harvesting in patients with long-term dCVCs compared to the other categories. A high complication rate has also recently been reported by Goldberg et al 14 where 50% of their patients with a semipermanent dCVC experienced at least one episode of catheter occlusion during harvesting which required thrombolytic therapy or cancellation of the procedure. However, in our study only four out of 66 (6%) harvest occasions had to be interrupted due to occlusion. A completely different approach is to use a technique for translumbar catheterisation of the inferior vena cava. 11, 12 Using that technique, thrombosis-related access failure occurred in 24%, but 64% of the dCVCs were still in place during PBSC rescue.
11
In our study half of the long-term dCVCs were removed due to complications. Most of the long-term dCVCs were removed before the start of high-dose treatment. This also occurred in patients with catheter complications who experienced an increased number of febrile days while not neutropenic. We have no clear explanation for the fact that most of the catheters were infected when patients were not immunosuppressed. Several factors are known to influence risk of infection associated with the use of ordinary CVCs; number of lumens, insertion site, repeated catheterization, duration of catheterization, type of dressing, experience of personnel inserting the device and that of special intravenous therapy personnel. 13, [15] [16] [17] However, the complication rate, in our study, of the remaining long-term dCVCs during the high-dose treatment was comparable with that of other reports concerning conventional CVCs. 18, 19 To our knowledge, there is only one previous study describing the use of long-term dCVCs in adults during harvesting and subsequent high-dose treatment with PBSC rescue. 3 In that study, Meisenberg et al 3 showed that 16% of long-term dCVCs used in this setting were removed prematurely due to complications and 7% of the long-term dCVCs were infected late. The difference in infection rate compared to that seen in our study may in part be explained by the use of prophylactic low-dose warfarin. An association between infection and thrombosis has been described in patients with cancer and CVC. 20 There were also more frequent complications in long-term dCVCs inserted by less skilled surgeons in the Meisenberg study. Thirteen surgeons inserted the long-term dCVCs in this study and results may have been better if fewer surgeons had been involved. Another difference between our study and the study by Meisenberg et al was the management of exit site dressing changes. In the Meisenberg study, patients were instructed on how to change their long-term dCVC exit site dressing, but whether or not this had an impact on the risk for infection is difficult to evaluate.
Our results also demonstrate that occurrence of longterm dCVC-related thrombosis was related to a history of earlier deep venous thrombosis. Therefore, it seems reasonable that patients with a history of venous thrombosis should avoid long-term dCVCs. If this group of patients still have a catheter, a very low dose of warfarin (1 mg/24 h) may protect against thromboses without inducing a haemorrhagic state. 3, 21, 22 Furthermore, if cath-eter-related thromboses do occur, the catheter may successfully be left in place during full-dose anticoagulation therapy. 3 As a consequence of our high complication rate with long-term dCVCs, both during harvest and later, we have changed our policy in patients unable to have a PVC. These patients now have a short-term dCVC, which is removed after harvesting is complete. This approach is also supported by other reports. 2, 23 In conclusion, on the basis of our experience we recommend that harvesting is performed via a PVC in patients with veins of good quality. If there is a need for a dCVC, a short-term catheter used only during the collection of PBSC is preferable. The long-term dCVCs cannot be recommended due to the high number of complications.
Further studies are needed to optimize different approaches towards venous access, starting from mobilisation before stem cell harvest until recovery after high-dose chemotherapy with stem cell rescue.
